AtheroGenics Converts Ch. 7 Bankruptcy Into Ch. 11

Blaming a "substantial debt burden" that has threatened the development of a key diabetes drug, pharmaceutical company AtheroGenics Inc. asked a court on Monday to convert an involuntary Chapter 7 petition...

Already a subscriber? Click here to view full article